Literature DB >> 9105637

Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.

S E Lind1, P W Callas, E A Golden, K A Joyner, T L Ortel.   

Abstract

Monitoring of oral anticoagulant therapy is usually undertaken with the prothrombin time (PT), which is influenced by factors II, X, and VII. A number of studies have suggested that the prothrombin (factor II) level may be the most important determinant of the therapeutic efficacy of these drugs. Although some studies suggest that oral anticoagulants induce a similar residual level of plasma vitamin K-dependent proteins, others have called this into question. We therefore measured plasma levels of factors II, X, and VII in 50 patients undergoing chronic Warfarin therapy. The plasma levels of factors II, X, and VII were significantly different. Although the factor X levels of all plasmas were < 30%, levels of factors II and VII were > 30% in 14% and 50% of the samples, respectively. Multivariable analysis showed factor II levels to be the least significant of the three factors measured in determining the international normalized ratio of plasma or whole blood. Thus, plasma levels of the vitamin K-dependent coagulation factors are not equal in patients on chronic Warfarin therapy. If factor II (prothrombin) levels are indeed the major determinants of the therapeutic efficacy of Warfarin, alternative means of monitoring that more accurately reflects prothrombin levels should be evaluated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105637     DOI: 10.1097/00001721-199701000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing.

Authors:  Lisa M Baumann Kreuziger; Yvonne H Datta; Andrew D Johnson; Nicole D Zantek; Ryan Shanley; Mark T Reding
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

2.  Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage.

Authors:  David L Brody; Venkatesh Aiyagari; Angela M Shackleford; Michael N Diringer
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs).

Authors:  Megan C Herink; Yan F Zhuo; Craig D Williams; Thomas G DeLoughery
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

Review 4.  Stroke prevention treatment of patients with atrial fibrillation: old and new.

Authors:  Simerpreet Bal; Pawan Ojha; Michael D Hill
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

5.  Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2.

Authors:  Ravi Sarode; Katsuyuki Fukutake; Masahiro Yasaka; Michael A Tortorici; Antoinette Mangione; Marc Pfister; Adam Cuker
Journal:  Blood Adv       Date:  2020-09-08

6.  Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients.

Authors:  Cezary Watala; Jacek Golanski; Przemyslaw Kardas
Journal:  Thromb J       Date:  2003-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.